Compare · ELVN vs NVO
ELVN vs NVO
Side-by-side comparison of Enliven Therapeutics Inc. (ELVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 84.8x ELVN ($2.25B).
- Over the past year, ELVN is up 89.1% and NVO is down 45.6% - ELVN leads by 134.7 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 9 for ELVN).
- Company
- Enliven Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $44.90+24.29%
- $42.79+1.42%
- Market cap
- $2.25B
- $191.15B
- 1M return
- -6.71%
- -7.76%
- 1Y return
- +89.06%
- -45.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 8
- 8
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELVN
- Enliven Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
- Director Kunkel Lori Anne sold $345,351 worth of shares (10,000 units at $34.54) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 51,884 units (SEC Form 4)
- Stifel initiated coverage on Enliven Therapeutics with a new price target
- SEC Form 144 filed by Enliven Therapeutics Inc.
- Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
- Enliven Therapeutics to Present at Upcoming Investor Conferences
- CHIEF MEDICAL OFFICER Collins Helen Louise sold $198,971 worth of shares (5,000 units at $39.79) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)
- Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
- Guggenheim initiated coverage on Enliven Therapeutics with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care